Neil M. Iyengar, MD

Articles

Unveiling the Latest in HER2+ Breast Cancer and Beyond With Drs Sara Hurvitz and Neil Iyengar

December 12th 2024

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Investigational Agents, Clinical Trials for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss novel agents in the pipeline for patients with advanced HER2-positive breast cancer.

Frequent AEs and Management Approaches for Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss commonly reported adverse effects from HER2-positive breast cancer treatment and appropriate management strategies for them.

Treatment Decisions in Advanced HER2+ Breast Cancer With CNS Metastases

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss how to decide on treatment for patients with advanced or metastatic HER2-positive breast cancer who have central nervous system metastases.

Optimal Management Strategies in Advanced HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.

Current Prognosis for Advanced or Metastatic HER2+ Breast Cancer

July 12th 2024

Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the prognosis for patients with advanced or metastatic HER2-positive breast cancer.

Dr. Iyengar on the Benefit of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer After T-DM1

January 24th 2023

Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.

HER2+ mBC Trials in Progress and Other Exciting Prospects on the Horizon

October 20th 2022

Dr. Neil M. Iyengar closes the discussion with preliminary results from a phase I study, thoughts on use of biosimilars, and other in-progress trials of interest.

Considering Pulmonary Status: Monitoring for Interstitial Lung Disease

October 20th 2022

Clinically relevant advice for the monitoring and management of pulmonary complications in patients with HER2+ mBC.

New Data and Guidelines Concerning HER2+ mBC Therapy Sequencing

October 13th 2022

Discussion centered around the latest data and guideline updates, and how these changes affect therapy sequencing in the first, second, and third lines of treatment.

The Impact of Brain Metastases on Treatment Selection in Patients with HER2+ mBC

October 13th 2022

Insights concerning the selection of effective treatment approaches for patients with HER2+ mBC presenting with brain metastases and other complications.

Review of Key Data Supporting Recent Developments in the HER2+ mBC Landscape

October 6th 2022

An expert breast medical oncologist discusses recent changes to HER2+ mBC treatment guidelines due to key findings from the DESTINY-Breast03 trial.

The Current Standard-of-Care for Patients with HER2+ Metastatic Breast Cancer

October 6th 2022

Neil M. Iyengar, MD briefly reviews the standard-of-care first-line treatment for patients with metastatic HER2+ breast cancer as well as historical approaches to progression after first-line treatment.

Considering Novel Therapy for HER2+ Metastatic Breast Cancer

April 29th 2022

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Patient Profile 2: 3L Therapy for Triple-Positive mBC

April 29th 2022

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Patient Profile 1: Sequencing Therapies in HER2+ mBC

April 15th 2022

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

Patient Profile 1: Second-Line Therapy for HER2+ mBC

April 15th 2022

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.